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BACKGROUND
Epidemiologic and preclinical data suggest that higher intake and serum levels of 
vitamin D and higher intake of calcium reduce the risk of colorectal neoplasia. To 
further study the chemopreventive potential of these nutrients, we conducted a 
randomized, double-blind, placebo-controlled trial of supplementation with vita-
min D, calcium, or both for the prevention of colorectal adenomas.
METHODS
We recruited patients with recently diagnosed adenomas and no known colorectal 
polyps remaining after complete colonoscopy. We randomly assigned 2259 partici-
pants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), both, 
or neither in a partial 2×2 factorial design. Women could elect to receive calcium 
plus random assignment to vitamin D or placebo. Follow-up colonoscopy was 
anticipated to be performed 3 or 5 years after the baseline examinations, accord-
ing to the endoscopist’s recommendation. The primary end point was adenomas 
diagnosed in the interval from randomization through the anticipated surveillance 
colonoscopy.
RESULTS
Participants who were randomly assigned to receive vitamin D had a mean net 
increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter, relative to 
participants given placebo. Overall, 43% of participants had one or more adeno-
mas diagnosed during follow-up. The adjusted risk ratios for recurrent adenomas 
were 0.99 (95% confidence interval [CI], 0.89 to 1.09) with vitamin D versus no 
vitamin D, 0.95 (95% CI, 0.85 to 1.06) with calcium versus no calcium, and 0.93 
(95% CI, 0.80 to 1.08) with both agents versus neither agent. The findings for 
advanced adenomas were similar. There were few serious adverse events.
CONCLUSIONS
Daily supplementation with vitamin D3 (1000 IU), calcium (1200 mg), or both after 
removal of colorectal adenomas did not significantly reduce the risk of recurrent 
colorectal adenomas over a period of 3 to 5 years. (Funded by the National Cancer 
Institute; ClinicalTrials.gov number, NCT00153816.)
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Vitamin D, an essential nutrient that is important for bone mineralization and calcium homeostasis,1 also has effects 
beyond bone and calcium. Many studies have 
shown it to be antineoplastic, particularly in the 
colorectum. In in vitro studies, vitamin D and its 
analogues have been shown to inhibit prolifera-
tion, induce differentiation, inhibit angiogenesis, 
and promote apoptosis in epithelial tissues.2,3 
High vitamin D intake inhibits experimental 
carcinogenesis,2,3 even in animals that are vita-
min D–replete.4 Observational studies of vitamin D 
intake5-7 and serum levels of 25-hydroxyvitamin 
D8-10 have shown inverse associations between 
these measures and the risk of colorectal cancer 
or adenoma.8-10 Trials of vitamin D supplementa-
tion have not shown a decrease in the incidence 
of colorectal cancer in association with supplemen-
tation,11-14 but these studies were limited by small 
numbers of events,11-13 low vitamin D doses,14 and 
relatively short follow-up periods for invasive 
cancer end points.11-14
High calcium intake is also associated with 
lower risks of colorectal neoplasia. Increases in 
dietary calcium have been shown to inhibit large-
bowel carcinogenesis in animal models,15 and 
epidemiologic studies have shown lower risks of 
colorectal cancer and adenomas in association 
with higher calcium intake.16 Trials of calcium 
supplementation for adenoma prevention have 
shown reduced risks.17-19 Moreover, calcium and 
vitamin D may have synergistic chemopreventive 
effects against colorectal neoplasia.20,21
To further investigate the chemopreventive 
potential of vitamin D and calcium, we conducted 
a randomized trial of supplementation with cal-
cium, vitamin D3, or both for the prevention of 
new colorectal adenomas in persons with a re-
cent history of adenomas. We hypothesized that 
supplementation would reduce the risk of adeno-
ma and that both agents together would reduce 
the risk more than calcium alone. Our secondary 
hypotheses addressed the relationship between 
vitamin D supplementation and the risk of ad-
vanced adenoma, as well as the effects of vita-
min D supplementation among persons with 
baseline 25-hydroxyvitamin D levels in blood that 
were below the study median, as compared 
with the effects in persons with levels above the 
median.
Me thods
Participants
We conducted this randomized, multicenter, 
double-blind, placebo-controlled trial at 11 aca-
demic medical centers and associated medical 
practices in the United States. Enrollment of 
patients took place from July 2004 through July 
2008. Staff members at each center enrolled 
patients 45 to 75 years of age who had at least 
one colorectal adenoma removed within 120 days 
before enrollment, had no remaining polyps after 
a complete colonoscopy, and were anticipated to 
undergo a 3-year or 5-year colonoscopic follow-
up examination recommended by the treating 
endoscopist. Eligible patients were in good gen-
eral health and did not have familial colorectal 
cancer syndromes or serious intestinal disease. 
We did not include patients who had conditions 
that indicated that the study agents would pose 
a health risk (e.g., a history of kidney stones or 
hyperparathyroidism) or who had conditions that 
would indicate a need for either agent (e.g., osteo-
porosis). We also did not include patients who 
had a serum calcium level that was outside the 
normal range, a creatinine level that was more 
than 20% above the upper limit of the normal 
range, or a 25-hydroxyvitamin D level that was 
lower than 12 ng per milliliter or higher than 
90 ng per milliliter.
Study Design and Oversight
In a partial factorial design, we evaluated four 
regimens, all of which involved two identical 
tablets taken daily: 1000 IU of vitamin D3, 1200 mg 
of calcium as carbonate, both agents, or placebo. 
Women could elect to be randomly assigned to 
receive either calcium or calcium plus vitamin D 
(two-group randomization); all other patients 
were randomly assigned to receive one of the 
four regimens (full factorial randomization). 
The doses of study agents were chosen to in-
crease the total intake substantially, with a mar-
gin of safety below the highest mean daily intake 
level believed unlikely to cause adverse effects in 
most people at the time that the trial began 
(2000 IU of vitamin D and 2.5 g of calcium).22 In 
accordance with the protocol, study treatment 
was to continue until the anticipated 3-year or 
5-year colonoscopic examination.
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At enrollment, participants provided informa-
tion regarding demographic data, medical histo-
ry, medications, nutritional supplements, behav-
ioral factors, and diet (using the Block Brief 2000 
food frequency questionnaire [Nutritionquest]). 
Enrollment was followed by a placebo run-in 
period of 56 to 84 days to identify and exclude 
participants who were considered unlikely to fol-
low study procedures. Subsequent randomiza-
tion by the coordinating center was performed 
with the use of computer-generated random 
numbers with permuted blocks and stratification 
according to clinical center, sex, anticipated 
colonoscopic examination at 3 years or 5 years, 
and full factorial or two-group randomization. 
All study staff were unaware of the treatment 
assignments, with the exception of the data ana-
lyst and statistician, some of the programmers, 
and pharmacy personnel.
Participants agreed to avoid taking study 
agents outside the trial. However, because of in-
creasing publicity regarding the possible bene-
fits of these supplements (especially vitamin D), 
daily personal use of up to 1000 IU of vitamin D, 
400 mg of elemental calcium, or both were per-
mitted, although discouraged, from April 2008 
onward.
Participants were contacted by telephone 
every 6 months and queried regarding adherence 
to study agents, illnesses, medication and sup-
plement use, dietary calcium intake (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org), and colorectal 
procedures. Records were collected that included 
data on major medical events, colorectal surgical 
procedures, and endoscopic examinations. Two 
physicians who were unaware of the study group 
assignments adjudicated the diagnosis of adverse 
events. Bottles of study tablets were mailed to 
participants every 4 months. Patients who wanted 
to take a multivitamin were offered a special 
preparation that did not include calcium and 
vitamin D. The study intervention ended on 
August 31, 2013; the treatment-phase follow-up 
continued until November 30, 2013, to accom-
modate the final 5-year participants.
Blood levels of 25-hydroxyvitamin D, calcium, 
and creatinine were measured at baseline and at 
year 1, as well as at year 3 for participants with 
5-year surveillance cycles. The level of 25-hydroxy-
vitamin D was also measured shortly before the 
end-of-treatment examination. The laboratory 
methods are described in the Supplementary Ap-
pendix. Levels of 25-hydroxyvitamin D were 
seasonally adjusted according to the month in 
which the blood was drawn (see the Supplemen-
tary Appendix). The net change in 25-hydroxyvita-
min D levels was defined as the posttreatment 
level minus the pretreatment level in participants 
who received vitamin D, minus that difference in 
participants who were given no vitamin D.
The study end points included all adenomas 
that were diagnosed in any colorectal endo-
scopic or surgical procedure at least 1 year after 
randomization and up to 6 months after the 
anticipated 3-year or 5-year colonoscopic exami-
nation. A single study pathologist who was un-
aware of the treatment assignments reviewed the 
slides for all excised colorectal lesions. We dis-
tinguished between lesions that were proximal 
to the splenic flexure and lesions that were more 
distal. Advanced adenomas were defined as those 
with cancer, high-grade dysplasia, more than 
25% villous features, or an estimated diameter 
of at least 1 cm. Study diagnoses were compared 
with the diagnoses made by the pathologists at 
the clinical centers. Discrepancies were resolved 
by means of a detailed adjudication procedure 
(see the Supplementary Appendix).
The study was conducted and reported in ac-
cordance with the study protocol, which is avail-
able at NEJM.org. The authors designed the study, 
analyzed the data, wrote the manuscript, and 
vouch for the completeness and accuracy of the 
data and analysis. Pfizer Consumer Healthcare 
provided the study agents. No institution or 
company affected the analysis or the decision to 
submit the manuscript for publication.
All participants provided written informed 
consent; the research was approved by the insti-
tutional review board at each center. An indepen-
dent data and safety monitoring committee 
oversaw the study.
Statistical Analysis
In our primary analysis, we compared the risk of 
one or more adenomas after randomization to 
vitamin D versus no vitamin D, calcium versus 
no calcium, and calcium plus vitamin D versus 
calcium alone. Participants who did not undergo 
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the anticipated colonoscopic examination at 3 years 
or 5 years were included in the analysis if they 
had had a colonoscopic examination performed 
at least 1 year after randomization. The sample 
size and statistical power considerations are 
described in the Supplementary Appendix.
In the prespecified primary analysis, contin-
gency tables and standard chi-square tests were 
used for the comparison of adenoma occurrence 
among randomized groups. The calcium analy-
ses included only the participants who under-
went full-factorial randomization. Subsequent 
multivariable generalized linear models for bi-
nary data were used to estimate adjusted risk 
ratios and confidence intervals. The covariates 
were age, sex, clinical center, number of baseline 
adenomas (one, two, or three or more), antici-
pated 3-year versus 5-year surveillance interval, 
and two-group versus full-factorial randomiza-
tion. Clinical centers were grouped geographi-
cally when necessary because of sparse data. 
One subgroup analysis was prespecified: the ef-
fects of vitamin D in participants with baseline 
25-hydroxyvitamin D levels below the overall 
median level were compared with the effects in 
those with levels above the median level. Eight 
additional post hoc subgroup analyses were con-
ducted, as described in Figure 1. Interactions 
were assessed with the use of Wald tests. For 
interactions with variables that had more than 
two levels, we used a one-degree-of-freedom test 
for trend over medians within strata. In all analy-
ses of randomly assigned treatments, participants 
were evaluated according to their assigned treat-
Figure 1. Subgroup Analysis of the Effects of Supplementation with Calcium or Vitamin D on the Development of One or More Adenomas.
The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. NSAID denotes nonsteroidal anti-
inflammatory drug.
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ment group, regardless of their adherence to the 
study treatment and procedures. Sensitivity analy-
ses were conducted with imputation of missing 
end points as either adenomas or no adenomas.
In a post hoc observational analysis, we simi-
larly assessed associations between adenoma 
risk and baseline serum 25-hydroxyvitamin D 
levels among participants who were not ran-
domly assigned to take vitamin D, as well as the 
association between adenoma risk and baseline 
calcium intake among participants who were not 
randomly assigned to receive calcium. The analy-
ses were adjusted for a number of covariates, 
including (but not limited to) age, clinical center, 
surveillance interval (3 or 5 years), and number of 
baseline adenomas (one, two, or three or more).
Two-sided P values of less than 0.05 were 
considered to indicate statistical significance. 
Statistical analyses were conducted with the use 
of SAS software, version 9.4 (SAS Institute), and 
STATA software, version 12 (StataCorp).
R esult s
Participants
During the period from July 2004 through July 
2008, the study staff screened colonoscopy and 
pathology reports and found 19,083 apparently 
eligible patients (Fig. S1 in the Supplementary 
Appendix). Ultimately, 2813 participants entered 
the run-in period, and 2259 underwent random-
ization. The study population was middle-aged 
or older; most patients were non-Hispanic men, 
and more than 35% of the patients were obese 
(Table 1). A total of 11% of the participants had 
three or more adenomas at baseline, and 18% 
had one or more advanced adenomas. There 
were no material differences between treatment 
groups with regard to personal characteristics 
(Table 1). Fifteen patients who underwent ran-
domization and were included in the analysis 
were later found not to have met all eligibility 
criteria (see the Supplementary Appendix).
Adherence to the Study Procedures
The reported adherence to colonoscopy was excel-
lent. Only 67 participants (3.0%) did not have a 
colonoscopic examination with associated histo-
logic data at least 1 year after randomization, 
and 104 participants (4.6%) dropped out of the 
study, were lost to follow-up, or died; this left 
2088 participants (92.4%) in the analysis (Fig. S1 
in the Supplementary Appendix). Only approxi-
mately 1% of the colonoscopic examinations 
failed to reach the cecum; in 2.0% of proce-
dures, the preparation of the colon was deemed 
“poor,” and in 6.8% it was deemed “fair.” The 
times to final colonoscopic examination are 
summarized in Table S2 in the Supplementary 
Appendix. A total of 1598 participants (77%) had 
a surveillance colonoscopic examination within 
6 months before or after the anticipated 3-year 
or 5-year follow-up examination. A total of 60 
participants (2.9%) had more than one colono-
scopic examination during follow-up.
During the first year after randomization, 
1974 of the 2259 participants who underwent 
randomization (87.4%) reported taking 80% or 
more of the study tablets; in the final year of 
treatment, 1663 participants (73.6%) reported 
this level of adherence. During the treatment 
period, 1719 participants (76.1%) reported tak-
ing at least 80% of the study tablets, and 1949 
(86.3%) reported taking at least 50%. Only 98 of 
2251 participants for whom data on personal 
vitamin supplementation were available (4.4%) 
reported on two or more semiannual interviews 
that they took personal vitamin D supplements 
of 1000 IU or more daily, 74 (3.3%) reported that 
they took 400 mg or more of calcium daily, and 
78 (3.5%) reported that they took 500 to less 
than 1000 IU of vitamin D. The mean (±SD) net 
increase in serum 25-hydroxyvitamin D among 
participants randomly assigned to vitamin D was 
7.83±13.4 ng per milliliter in a blood sample 
drawn shortly before the end of treatment.
Occurrence of Adenomas
In follow-up examinations, 3131 lesions that were 
potentially neoplastic were seen in 1301 partici-
pants. Pathological evaluations were available for 
3012 lesions in 1280 participants. For 119 le-
sions, the tissue was lost, fulgurated without 
biopsy, or unsuitable for diagnosis; this left 2059 
(99%) of the examined participants for whom 
we could determine adenoma status. Adenomas 
were diagnosed in 880 participants (43%).
Effects of Supplementation
The study interventions, alone or in combina-
tion, did not have a significant effect on the risk 
of adenoma (Table 2). The adjusted risk ratio for 
any adenoma among patients taking vitamin D 
as compared with patients who did not take vita-
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min D was 0.99 (95% confidence interval [CI], 
0.89 to 1.09), and the adjusted risk ratio among 
patients taking calcium as compared with those 
who did not take calcium was 0.95 (95% CI, 0.85 
to 1.06). Among patients taking vitamin D plus 
calcium versus those taking calcium alone, the 
adjusted risk ratio was 1.01 (95% CI, 0.88 to 
1.15). The adjusted risk ratio among patients 
taking vitamin D plus calcium versus those tak-
ing neither agent was 0.93 (95% CI, 0.80 to 
1.08). The findings for advanced adenomas also 
did not suggest meaningful effects. The results 
for proximal adenomas were similar to those for 
distal adenomas (Table S3 in the Supplementary 
Appendix).
In the subgroup analyses, we found almost 
no significant effects of supplementation (Fig. 1, 
and Fig. S2 in the Supplementary Appendix). The 
findings were similar among participants with 
baseline 25-hydroxyvitamin D levels below the 
study median of 23.2 ng per milliliter and those 
with levels above the study median. However, 
body-mass index (BMI) appeared to modify the 
effects of calcium on adenoma risk (P = 0.02): the 
lower the BMI, the greater the response to cal-
cium supplementation. Findings with respect to 
advanced adenomas were broadly similar to 
those for all adenomas (Fig. 1, and Fig. S2 in the 
Supplementary Appendix). The findings did not 
differ significantly between participants who 
were using vitamin D or calcium supplements at 
baseline and those who were not or between 
those who had advanced adenomas at baseline 
and those who did not (Tables S4, S5, and S6 in 
the Supplementary Appendix). There were no 
indications of effects in a per-protocol analysis, 
nor was there an association between adenoma 
risk and changes in 25-hydroxyvitamin D levels 
Treatment Assignment One or More Adenomas† One or More Advanced Adenomas‡
No. of Patients/
Total No. (%)
Risk Ratio 
(95% CI)§
No. of Patients/ 
Total No. (%)
Risk Ratio 
(95% CI)§
Vitamin D vs. no vitamin D
No vitamin D 442/1035 (42.7) Reference 98/1042 (9.4) Reference
Vitamin D 438/1024 (42.8) 0.99 (0.89–1.09) 98/1032 (9.5) 0.99 (0.75–1.29)
Calcium vs. no calcium
No calcium 362/761 (47.6) Reference 77/764 (10.1) Reference
Calcium 345/762 (45.3) 0.95 (0.85–1.06) 81/773 (10.5) 1.02 (0.76–1.38)
Calcium plus vitamin D vs. calcium 
alone
Calcium 259/655 (39.5) Reference 63/662 (9.5) Reference
Calcium plus vitamin D 259/643 (40.3) 1.01 (0.88–1.15) 56/648 (8.6) 0.89 (0.63–1.26)
Calcium plus vitamin D vs. neither 
agent
Neither calcium nor vitamin D 183/380 (48.2) Reference 35/380 (9.2) Reference
Calcium plus vitamin D 174/381 (45.7) 0.93 (0.80–1.08) 37/387 (9.6) 0.99 (0.63–1.56)
*  The analyses of vitamin D versus no vitamin D included all participants who underwent randomization. The analyses  
of calcium versus no calcium and of vitamin D plus calcium versus neither agent were restricted to participants who 
underwent full factorial randomization. The analyses of vitamin D plus calcium versus calcium did not include partici-
pants who underwent full factorial randomization and were assigned to receive placebo or vitamin D alone.
†  P values, calculated with the use of a chi-square contingency-table test, are as follows: vitamin D versus no vitamin D, 
P = 0.98; calcium versus no calcium, P = 0.37; vitamin D plus calcium versus calcium, P = 0.79; and vitamin D plus calcium 
versus neither agent, P = 0.49.
‡  Denominators differ between adenomas and advanced adenomas because of missing data for lesion size and an as-
sumption that small lesions (<6 mm) with missing pathological data are not advanced adenomas (see the Supplementary 
Appendix).
§  Risk ratios were adjusted for age, clinical center, anticipated surveillance interval (3 or 5 years), a three-level variable for 
sex and type of randomization (male, female and two-group randomization, female and full factorial randomization), 
and number of baseline adenomas (1, 2, or ≥3).
Table 2. Risk Ratios for Colorectal Adenoma Outcomes According to Treatment Assignment.*
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or total calcium intake from baseline to shortly 
before the end of treatment (Tables S7 and S8 in 
the Supplementary Appendix). However, there 
was a suggestion that supplementation with vita-
min D or calcium conferred lower risks among 
participants with longer surveillance (and treat-
ment) intervals, although the differences were 
not significant (Fig. 1, and Table S9 in the Sup-
plementary Appendix). The sensitivity analysis 
did not suggest that missing data distorted the 
primary analyses (Table S10 in the Supplemen-
tary Appendix).
Adverse events are shown in Table 3. Calcium 
supplementation was associated with a small, 
nonsignificantly greater risk of urolithiasis than 
no calcium supplementation, and vitamin D sup-
plementation was associated with a nonsignifi-
cantly lower risk of urolithiasis than no vita-
min D supplementation. Participants who were 
randomly assigned to take calcium had slightly 
higher serum creatinine levels than did partici-
pants who were not assigned to take calcium; 
the difference was of borderline significance. In 
addition, participants assigned to take calcium 
had significantly fewer myocardial infarctions 
than participants who were assigned to no cal-
cium supplementation.
The observational associations between adeno-
ma occurrence and baseline serum 25-hydroxyvi-
tamin D level or baseline calcium intake roughly 
paralleled the findings for supplementation with 
vitamin D or calcium (Table 4). Among partici-
pants who were not given vitamin D, baseline 
25-hydroxyvitamin D levels were not significantly 
associated with adenoma risk (risk ratio, quar-
tile 4 vs. quartile 1, 0.98; 95% CI, 0.79 to 1.21). 
Adverse Event Vitamin D versus No Vitamin D Calcium versus No Calcium
No Vitamin D 
(N = 1129)
Vitamin D 
(N = 1130) P Value
No Calcium 
(N = 835)
Calcium 
(N = 840) P Value
number (percent) number (percent)
Death 12 (1.1) 15 (1.3) 0.56 12 (1.4) 13 (1.5) 0.85
Myocardial infarction with or with-
out revascularization
7 (0.6) 8 (0.7) 0.80 9 (1.1) 2 (0.2) 0.03
Revascularization without myocar-
dial infarction
11 (1.0) 12 (1.1) 0.84 8 (1.0) 12 (1.4) 0.38
Stroke 5 (0.4) 9 (0.8) 0.28 5 (0.6) 3 (0.4) 0.51
Transient ischemic attack 1 (0.1) 3 (0.3) 0.62 3 (0.4) 0 0.12
Cancer
Any 61 (5.4) 47 (4.2) 0.17 46 (5.5) 46 (5.5) 0.98
Colorectal 2 (0.2) 3 (0.3) 1.00 0 2 (0.2) 0.50
Urolithiasis 28 (2.5) 19 (1.7) 0.18 15 (1.8) 20 (2.4) 0.40
Hypercreatininemia† 67 (6.0) 57 (5.1) 0.35 40 (4.9) 58 (7.0) 0.06
Hypercalcemia‡ 28 (2.5) 25 (2.2) 0.67 5 (0.6) 17 (2.0) 0.01
Hypercalcemia after albumin 
 correction§
4 (0.4) 3 (0.3) 1.00 0 2 (0.2) 0.50
Fracture 64 (5.7) 55 (4.9) 0.39 43 (5.1) 37 (4.4) 0.47
*  The table includes all confirmed events up to 30 days after the cessation of study treatment in all participants who under-
went randomization. Data are the numbers of participants who had one or more occurrences of an adverse event and 
their percentage among all participants who were randomly assigned to the given group.
†  Hypercreatininemia was defined as a creatinine level in the blood sample drawn at year 1 (all participants) or year 3 
(participants with a 5-year follow-up) that was above the normal range among participants who had creatinine levels  
in the normal range at baseline; 31 participants had baseline creatinine levels that were above the normal range. Data 
were available for 1113 participants in the group that received no vitamin D, 1115 participants in the group that received 
vitamin D, 822 participants in the group that received no calcium, and 825 participants in the group that received calcium.
‡  Hypercalcemia was defined as a calcium level in the blood sample drawn at year 1 or year 3 that was above the normal 
range, before albumin correction.
§  Albumin correction was not available for 12 participants.
Table 3. Adverse Events.*
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The results for baseline calcium intake among 
participants who were not given calcium were 
similar (risk ratio, quartile 4 vs. quartile 1, 0.95; 
95% CI, 0.75 to 1.19). We also found no obser-
vational associations between the risk of ad-
vanced adenomas and baseline serum 25-hydrox-
yvitamin D level or baseline calcium intake.
Discussion
Contrary to our hypotheses, neither 1000 IU of 
vitamin D3 nor 1200 mg of calcium, taken daily 
alone or in combination, reduced the risk of 
colorectal adenomas. The findings were similar 
with regard to the risk of advanced adenomas, 
and vitamin D supplementation was ineffective 
even among participants who had lower baseline 
serum 25-hydroxyvitamin D levels. Unplanned 
subgroup analyses based on participant charac-
teristics at baseline yielded similar results, with 
the exception of a lower risk of adenomas in as-
sociation with calcium supplementation among 
participants with lower BMIs. Because of the 
number of subgroups examined, this finding may 
be due to chance. In observational analyses, we 
also found no association between either baseline 
Quartile of Level or Intake* Baseline Serum 25-Hydroxyvitamin D Level† Baseline Dietary Calcium Intake‡
No. of Patients/
Total No. (%)
Adjusted Risk 
Ratio 
(95% CI)§
Adjusted Risk Ratio 
per 10 ng/ml 
(95% CI)
No. of Patients/
Total No. (%)
Adjusted Risk 
Ratio 
(95% CI)¶
Adjusted Risk 
Ratio per 200 mg 
(95% CI)
Participants with one or more 
adenomas
0.98 
(0.90–1.07)
0.99 
(0.93–1.04)
Quartile 1 108/256 (42.2) Reference 89/179 (49.7) Reference
Quartile 2 115/271 (42.4) 1.02 
(0.83–1.25)
94/170 (55.3) 1.17 
(0.95–1.46)
Quartile 3 117/257 (45.5) 1.06 
(0.86–1.30)
69/170 (40.6) 0.85 
(0.65–1.08)
Quartile 4 102/251 (40.6) 0.98 
(0.79–1.21)
84/184 (45.7) 0.95 
(0.75–1.19)
Participants with one or more 
advanced adenomas‖
0.91 
(0.71–1.16)
0.94 
(0.80–1.10)
Quartile 1 25/257 (9.7) Reference 21/176 (11.9) Reference
Quartile 2 28/270 (10.4) 1.11 
(0.66–1.88)
15/176 (8.5) 0.72 
(0.38–1.36)
Quartile 3 21/263 (8.0) 0.83 
(0.47–1.46)
19/170 (11.2) 0.96 
(0.52–1.75)
Quartile 4 24/252 (9.5) 1.06 
(0.61–1.83)
18/185 (9.7) 0.82 
(0.44–1.53)
*  For 25-hydroxyvitamin D, quartiles of seasonally adjusted values were as follows: quartile 1, ≤18.411 IU; quartile 2, 18.412 to 23.178 IU; 
quartile 3, 23.179 to 29.326 IU; and quartile 4, ≥29.327 IU. For calcium intake, the quartiles were as follows: quartile 1, up to 435.7 mg; 
quartile 2, 437.8 to 596.7 mg; quartile 3, 596.8 to 831.2 mg; and quartile 4, ≥831.3 mg.
†  The analysis was restricted to participants who did not receive study vitamin D supplementation; risk ratios were adjusted for age, clinical 
center, anticipated surveillance interval (3 or 5 years), a three-level variable for sex and type of randomization (male, female and two-group 
randomization, female and full factorial randomization), number of baseline adenomas (one, two, or three or more), and calcium treatment 
assignment (participants who underwent two-group randomization are grouped with participants who underwent full factorial randomiza-
tion and received calcium).
‡  The analysis was restricted to participants who underwent full factorial randomization and did not receive study calcium supplementation; 
risk ratios were adjusted for age, clinical center, anticipated surveillance interval (3 or 5 years), sex, number of baseline adenomas (one, two, or 
three or more), and vitamin D treatment assignment; because of sparse data for advanced adenomas, clinical centers are grouped geographi-
cally into southeast (Georgia, North Carolina, South Carolina, and Puerto Rico), north (Ohio, New Hampshire, Iowa, and Minnesota), and 
west (Colorado, Texas, and California).
§  The P value for trend for adenomas was 0.86, and the P value for trend for advanced adenomas was 0.95.
¶  The P value for trend for adenomas was 0.33, and the P value for trend for advanced adenomas was 0.99.
‖  Denominators differ between adenomas and advanced adenomas because of missing data on lesion size and an assumption that small lesions 
(<6 mm) with missing pathological data are not advanced adenomas (see the Supplementary Appendix).
Table 4. Observational Association of Baseline Serum 25-Hydroxyvitamin D Level and Dietary Calcium Intake with Risk of Colorectal 
Adenoma.
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25-hydroxyvitamin D levels or dietary calcium 
intake and the risk of adenomas or advanced 
adenomas.
Our study dose of vitamin D (1000 IU per day) 
exceeded the currently recommended intake for 
adults up to 70 years of age (600 IU per day). 
However, a higher dose would have raised 25-hy-
droxyvitamin D levels in serum more markedly 
and provided a more sensitive test of vitamin D 
chemoprevention. Meta-analyses have summa-
rized the observational association between se-
rum 25-hydroxyvitamin D level and colorectal 
cancer as relative risks of 0.74 per 10 ng per 
milliliter,6 0.85 per 10 ng per milliliter,23 and 
0.96 per 100 IU per liter5 (0.85 per 10 ng per 
milliliter). These associations suggest that the net 
mean increase of 7.83 ng per milliliter in serum 
25-hydroxyvitamin D levels in our study might 
yield a relative risk between 0.80 and 0.88, 
which is outside our confidence limits for all 
adenomas. In this sense, our findings provide 
evidence against the strong observational asso-
ciation reported in these meta-analyses.
A report of increasing colorectal cancer risk 
with increasing 25-hydroxyvitamin D levels24 was 
included in one meta-analysis9 that yielded a 
summary relative risk of 0.94 per 10 nmol per 
liter (0.90 per 10 ng per milliliter). This suggests 
that the increase of 7.83 ng per milliliter in 
25-hydroxyvitamin D levels in our study might 
yield a relative risk of 0.92, which is within our 
confidence intervals and so statistically consis-
tent with our data. Meta-analyses of the relation-
ship between adenoma risk and serum 25-hydrox-
yvitamin D levels8,10 have shown summary 
relative risks between 0.82 and 0.93 per 20 ng per 
milliliter (0.93 to 0.97 per 7.75 ng per milliliter). 
Again, our data are consistent with this weaker 
association.8,10 A larger sample size, higher vita-
min D dose, or perhaps a longer intervention 
might have been required to detect these asso-
ciations. Also, the fact that vitamin D may have 
a weaker relationship with adenomas than with 
colorectal cancer might imply that vitamin D acts 
at a later stage of carcinogenesis than that at 
which adenomas develop.
In view of the strong data supporting a chemo-
preventive effect of calcium supplementation on 
colorectal carcinogenesis15,16,18,19 (including find-
ings in our own previous trial),17 it is surprising 
that we found no effect of calcium. However, the 
lack of association between baseline dietary cal-
cium intake and adenoma risk observed in our 
study population supports the negative findings 
for calcium in our trial. Whether the high preva-
lence of obesity in our study population explains 
the lack of a calcium effect requires further in-
vestigation.
Important adverse events in the trial were 
generally uncommon. However, calcium supple-
mentation resulted in an unexpected, small in-
crease in serum creatinine level,25 which was of 
uncertain clinical significance. There was a sig-
nificantly lower risk of myocardial infarction 
among participants randomly assigned to receive 
calcium, a finding that contrasts with recent 
evidence.26 The lower cancer risk associated with 
vitamin D supplementation and the smaller num-
ber of participants receiving vitamin D or calcium 
in whom fractures occurred were all compatible 
with chance.
Our trial had several strengths. It was large 
enough to detect modest chemopreventive effects, 
adherence to study treatment was high, and par-
ticipants largely avoided taking vitamin D and 
calcium in substantial amounts outside the 
study. We obtained findings from a follow-up 
colonoscopic examination in a high proportion 
of participants, and virtually all lesions under-
went central pathological review. However, the 
vitamin D dose was lower than the dose many 
experts now recommend, and it was used for a 
limited time. The trial was conducted among 
patients with a recent history of colorectal adeno-
mas, and the results might not apply to persons 
without such a history.
In summary, contrary to our expectation, 
supplementation with 1000 IU of vitamin D3, 
1200 mg of calcium, or both did not signifi-
cantly affect the risk of colorectal adenomas over 
a period of 3 to 5 years. We have no ready expla-
nation for the finding with regard to calcium 
supplementation, but the lack of an observa-
tional association between the risk of adenomas 
and baseline dietary calcium intake in our popu-
lation supports it. Our findings with regard to 
vitamin D are not inconsistent with a modest 
chemopreventive potential, but they do not sup-
port the more marked chemopreventive effect 
that has sometimes been posited.
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